Cargando…
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
PURPOSE: OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity. This phase I dose-escalation study of OPB-31121 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. MATE...
Autores principales: | Oh, Do-Youn, Lee, Se-Hoon, Han, Sae-Won, Kim, Mi-Jung, Kim, Tae-Min, Kim, Tae-You, Heo, Dae Seog, Yuasa, Miyuki, Yanagihara, Yasuo, Bang, Yung-Jue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614199/ https://www.ncbi.nlm.nih.gov/pubmed/25715763 http://dx.doi.org/10.4143/crt.2014.249 |
Ejemplares similares
-
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
por: Hayakawa, F, et al.
Publicado: (2013) -
Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
por: Yoo, Changhoon, et al.
Publicado: (2019) -
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer
por: Lee, Hyun Jung, et al.
Publicado: (2014) -
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
por: Kim, Su-Jung, et al.
Publicado: (2010) -
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)